Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Rare EGFR exon 20 S768I mutation predicts resistance to targeted therapy: a report of two cases.

× No keyword cloud information.

11 in total

Review 1. Epidermal growth factor receptor in non-small cell lung cancer.

Authors: Charles N Prabhakar
Journal: Transl Lung Cancer Res Date: 2015-04

2. Epidermal growth factor receptor exon 20 p.S768I mutation in non-small cell lung carcinoma: A case report combined with a review of the literature and investigation of clinical significance.

Authors: Giuseppina Improta; Angela Pettinato; Stefania Gieri; Giuseppa Scandurra; Wojciech Skovrider-Ruminski; Estrid Høgdall; Filippo Fraggetta
Journal: Oncol Lett Date: 2015-11-05 Impact factor: 2.967

Review 3. Response to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma with the Rare Epidermal Growth Factor Receptor Mutation S768I: a Retrospective Analysis and Literature Review.

Authors: Xiaoli Zhu; Qianming Bai; Yongming Lu; Peng Qi; Jianhui Ding; Jialei Wang; Xiaoyan Zhou
Journal: Target Oncol Date: 2017-02 Impact factor: 4.493

Review 4. Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy.

Authors: Yoshihisa Kobayashi; Tetsuya Mitsudomi
Journal: Cancer Sci Date: 2016-08-09 Impact factor: 6.716

5. Effectiveness of afatinib after ineffectiveness of gefitinib in an advanced lung adenocarcinoma patient with a single EGFR exon 20 S768I mutation: a case report.

Authors: Hua Duan; Yanmei Peng; Huijuan Cui; Yuqin Qiu; Qiang Li; Jingyi Zhang; Wen Shen; Chenyao Sun; Chufan Luo
Journal: Onco Targets Ther Date: 2018-04-23 Impact factor: 4.147

6. Better Progression-Free Survival in Elderly Patients with Stage IV Lung Adenocarcinoma Harboring Uncommon Epidermal Growth Factor Receptor Mutations Treated with the First-line Tyrosine Kinase Inhibitors.

Authors: Ming-Ju Tsai; Jen-Yu Hung; Mei-Hsuan Lee; Chia-Yu Kuo; Yu-Chen Tsai; Ying-Ming Tsai; Ta-Chih Liu; Chih-Jen Yang; Ming-Shyan Huang; Inn-Wen Chong
Journal: Cancers (Basel) Date: 2018-11-13 Impact factor: 6.639

Review 7. Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer.

Authors: Peter T Harrison; Simon Vyse; Paul H Huang
Journal: Semin Cancer Biol Date: 2019-09-25 Impact factor: 15.707

8. Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations.

Authors: Dan Chen; Zhengbo Song; Guoping Cheng
Journal: Onco Targets Ther Date: 2016-07-08 Impact factor: 4.147

9. Use of dedicated gene panel sequencing using next generation sequencing to improve the personalized care of lung cancer.

Authors: Coureche Guillaume Kaderbhai; Romain Boidot; Françoise Beltjens; Sandy Chevrier; Laurent Arnould; Laure Favier; Aurélie Lagrange; Bruno Coudert; François Ghiringhelli
Journal: Oncotarget Date: 2016-04-26

10. Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies.

Authors: Carman K M Ip; Patrick K S Ng; Kang Jin Jeong; S H Shao; Zhenlin Ju; P G Leonard; Xu Hua; Christopher P Vellano; Richard Woessner; Nidhi Sahni; Kenneth L Scott; Gordon B Mills
Journal: Nat Commun Date: 2018-11-02 Impact factor: 14.919